JP2015519398A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015519398A5 JP2015519398A5 JP2015517316A JP2015517316A JP2015519398A5 JP 2015519398 A5 JP2015519398 A5 JP 2015519398A5 JP 2015517316 A JP2015517316 A JP 2015517316A JP 2015517316 A JP2015517316 A JP 2015517316A JP 2015519398 A5 JP2015519398 A5 JP 2015519398A5
- Authority
- JP
- Japan
- Prior art keywords
- amount
- weight
- formulation
- added
- intermediate mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 claims 40
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 21
- 238000009472 formulation Methods 0.000 claims 15
- 238000000034 method Methods 0.000 claims 14
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 12
- 239000000243 solution Substances 0.000 claims 10
- 239000008351 acetate buffer Substances 0.000 claims 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 7
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims 7
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims 7
- 229960002216 methylparaben Drugs 0.000 claims 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 6
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 claims 6
- 229960000686 benzalkonium chloride Drugs 0.000 claims 6
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 6
- 208000002780 macular degeneration Diseases 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229960002474 hydralazine Drugs 0.000 claims 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 2
- 229940124274 edetate disodium Drugs 0.000 claims 2
- 239000001632 sodium acetate Substances 0.000 claims 2
- 235000017281 sodium acetate Nutrition 0.000 claims 2
- CAHQGWAXKLQREW-UHFFFAOYSA-N Benzal chloride Chemical compound ClC(Cl)C1=CC=CC=C1 CAHQGWAXKLQREW-UHFFFAOYSA-N 0.000 claims 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
- 208000008069 Geographic Atrophy Diseases 0.000 claims 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 208000011325 dry age related macular degeneration Diseases 0.000 claims 1
- 229960001484 edetic acid Drugs 0.000 claims 1
- 229960005384 hydralazine hydrochloride Drugs 0.000 claims 1
- ZUXNZUWOTSUBMN-UHFFFAOYSA-N hydralazine hydrochloride Chemical compound Cl.C1=CC=C2C(NN)=NN=CC2=C1 ZUXNZUWOTSUBMN-UHFFFAOYSA-N 0.000 claims 1
- 229910052707 ruthenium Inorganic materials 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261658304P | 2012-06-11 | 2012-06-11 | |
| US61/658,304 | 2012-06-11 | ||
| PCT/US2013/044617 WO2013188217A1 (en) | 2012-06-11 | 2013-06-06 | Therapeutic formulation and methods of treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015519398A JP2015519398A (ja) | 2015-07-09 |
| JP2015519398A5 true JP2015519398A5 (enExample) | 2016-07-21 |
Family
ID=49715792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015517316A Ceased JP2015519398A (ja) | 2012-06-11 | 2013-06-06 | 治療用製剤および処置の方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9254287B2 (enExample) |
| JP (1) | JP2015519398A (enExample) |
| KR (1) | KR20150032552A (enExample) |
| CN (1) | CN104768533A (enExample) |
| AU (1) | AU2013274582A1 (enExample) |
| HK (1) | HK1212225A1 (enExample) |
| SG (1) | SG11201408230VA (enExample) |
| TW (1) | TW201410245A (enExample) |
| WO (1) | WO2013188217A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015164419A1 (en) * | 2014-04-22 | 2015-10-29 | Acucela Inc. | Pupillometric assessment of retinal pharmacodynamics and responses therefrom |
| AU2015373050B2 (en) | 2014-12-30 | 2022-09-29 | Cell Cure Neurosciences Ltd. | RPE cell populations and methods of generating same |
| EP3697285A4 (en) * | 2017-10-17 | 2021-06-30 | Apeliotus Technologies, Inc. | FUNCTIONAL BIOMARKERS FOR STATIN THERAPY IN AGE-RELATED MACULAR DEGENERATION (AMD) |
| BR112020013238A2 (pt) | 2017-12-29 | 2020-12-01 | Cell Cure Neurosciences Ltd. | composição e método para formular células do epitélio pigmentar da retina bem como uso da dita composição para tratar uma condição retiniana |
| CN112007031A (zh) * | 2019-05-30 | 2020-12-01 | 杏国新药股份有限公司 | 眼用制剂 |
| US12109211B2 (en) | 2021-12-29 | 2024-10-08 | Endo Operations Limited | Hydralazine compositions and methods |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4055645A (en) | 1976-02-13 | 1977-10-25 | Merck & Co., Inc. | Novel anti-hypertensive compositions |
| FI873428A7 (fi) | 1986-08-18 | 1988-02-19 | Houston Biotechnology Incorporated | Silmälääketieteelliset koostumukset hermodegeneraatioiden hoitoon. |
| US4865599A (en) | 1986-08-18 | 1989-09-12 | Houston Biotechnology, Inc. | Ophthalmic compositions for treating nerve degeneration |
| WO1988005306A1 (en) * | 1987-01-23 | 1988-07-28 | The General Hospital Corporation | Atriopeptins, guanylate cyclase activators, and phosphodiesterase inhibitors as treatment for glaucoma, hydrocephalus and cerebral edema (cranial fluid volume dysfunction) |
| US5500230A (en) * | 1987-01-23 | 1996-03-19 | The General Hospital Corporation | Method for treatment of glaucoma with nitrogen containing guanylate cyclase activators |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| US5252607A (en) | 1992-01-24 | 1993-10-12 | Texas A&M University System | Treatment of low pressure glaucoma and ischemic retinal degeneration |
| US5459133A (en) | 1992-06-05 | 1995-10-17 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
| TW264385B (enExample) | 1993-05-14 | 1995-12-01 | Taiho Pharmaceutical Co Ltd | |
| US5422116A (en) * | 1994-02-18 | 1995-06-06 | Ciba-Geigy Corporation | Liquid ophthalmic sustained release delivery system |
| US5596011A (en) | 1995-04-06 | 1997-01-21 | Repine; Karen M. | Method for the treatment of macular degeneration |
| CA2252962A1 (en) | 1996-04-26 | 1997-11-06 | Fujisawa Pharmaceutical Co., Ltd. | Peripheral circulation improvers for ophthalmic tissues containing dihydropyridines |
| US6066675A (en) | 1996-09-13 | 2000-05-23 | The Regents Of The University Of California | Method for treatment of retinal diseases |
| ES2317650T3 (es) | 1996-10-28 | 2009-04-16 | Senju Pharmaceutical Co., Ltd. | Farmacos para mejorar trastornos circulatorios oculares. |
| EP1058546A4 (en) | 1998-03-06 | 2004-07-28 | Univ Texas | COMPILATIONS AND METHODS FOR THE TREATMENT OF MACULA DISEASES |
| US6028099A (en) | 1998-03-13 | 2000-02-22 | John Hopkins University, School Of Medicine | Use of an inhibitor of the protein tyrosine kinase pathway in the treatment of choroidal neovascularization |
| WO2000052479A2 (en) | 1999-03-05 | 2000-09-08 | University Of Iowa Research Foundation | Diagnostics and therapeutics for drusen associated ocular disorders |
| IL137429A0 (en) | 1999-07-28 | 2001-07-24 | Pfizer Prod Inc | Methods and compsitions for treating diseases and conditions of the eye |
| AU779991B2 (en) | 1999-08-10 | 2005-02-24 | Board Of Regents, The University Of Texas System | Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight |
| US6692759B1 (en) | 2000-06-28 | 2004-02-17 | The Regents Of The University Of California | Methods for preparing and using implantable substance delivery devices |
| US20030171375A1 (en) | 2002-02-13 | 2003-09-11 | Brazzell Romulus Kimbro | Method for treating ocular neovascular diseases |
| JP4599292B2 (ja) | 2002-10-30 | 2010-12-15 | エジソン ファーマシューティカルズ， インコーポレイテッド | 物理的−化学的特性に基づく治療用化合物の同定 |
| JP2004250347A (ja) | 2003-02-18 | 2004-09-09 | Ajinomoto Co Inc | 網膜虚血に基づく疾患の治療および／又は予防剤 |
| US20040214215A1 (en) | 2003-03-07 | 2004-10-28 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| EP1814535A4 (en) | 2004-11-08 | 2008-06-04 | Nitromed Inc | NITROSED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING EYE DISEASES |
| WO2006093864A1 (en) | 2005-02-28 | 2006-09-08 | Nitromed, Inc. | Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use |
| US8088773B2 (en) | 2005-05-12 | 2012-01-03 | The Texas A&M University System | Therapeutic compositions and methods |
-
2013
- 2013-06-06 AU AU2013274582A patent/AU2013274582A1/en not_active Abandoned
- 2013-06-06 JP JP2015517316A patent/JP2015519398A/ja not_active Ceased
- 2013-06-06 KR KR20157000568A patent/KR20150032552A/ko not_active Withdrawn
- 2013-06-06 WO PCT/US2013/044617 patent/WO2013188217A1/en not_active Ceased
- 2013-06-06 CN CN201380042670.3A patent/CN104768533A/zh active Pending
- 2013-06-06 US US13/912,149 patent/US9254287B2/en not_active Expired - Fee Related
- 2013-06-06 HK HK16100185.7A patent/HK1212225A1/xx unknown
- 2013-06-06 SG SG11201408230VA patent/SG11201408230VA/en unknown
- 2013-06-07 TW TW102120341A patent/TW201410245A/zh unknown
-
2016
- 2016-02-08 US US15/018,620 patent/US9694010B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013500977A5 (enExample) | ||
| HRP20221294T1 (hr) | Neuroaktivni steroidi, njihovi pripravci i uporabe | |
| JP2016535777A5 (enExample) | ||
| IL314873A (en) | Compositions and methods for treating disorders ameliorated by muscarnic receptor activation | |
| JP2016027060A5 (enExample) | ||
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| JP2015007136A5 (enExample) | ||
| RU2012103538A (ru) | Композиции и способы ингибирования пути jak | |
| CA2920410C (en) | Thienopiperidine derivative and use thereof | |
| SI2945620T1 (en) | Nitroxyl donors with improved therapeutic index | |
| NZ591205A (en) | Pharmaceutical compositions comprising clevidipine and methods for producing low impurity concentrations of the same | |
| JP2017517553A5 (enExample) | ||
| EP4218769A3 (en) | Treatment of oculopharyngeal muscular dystrophy by intravenous administration of trehalose | |
| MY173582A (en) | Extended-release formulation for reducing the frequency of urination and method of use thereof | |
| WO2016118040A8 (ru) | Гель, содержащий нифедипин и лидокаина гидрохлорид, его применение и способ приготовления с использованием нанотехнологий | |
| EA201591653A1 (ru) | Композиции для лечения глазных расстройств с применением дипиридамола | |
| MX2012007927A (es) | Antagonistas de dp2 y usos del mismo. | |
| EA201491870A1 (ru) | Способ лечения гиперурикемии у больных подагрой с помощью галофената или галофеновой кислоты и противовоспалительного агента | |
| BR112014004737A2 (pt) | composto de composição de cloridrato de ambroxol e método de preparação do composto | |
| EP2525819A4 (en) | IMMUNOTHERAPY COMPOSITIONS AND TREATMENT PROCEDURES | |
| BR112013025368A8 (pt) | Medicamento, método para preparar um medicamento útil para reduzir danos por derrame em um sujeito com derrame, método para preparar um medicamento útil para reduzir a pressão sanguínea e reduzir danos por derrame em um sujeito com derrame | |
| WO2013147000A1 (ja) | ２－アミノ－３－（４－ブロモベンゾイル）フェニル酢酸含有水性組成物 | |
| JP2013542262A5 (enExample) | ||
| EA201591218A1 (ru) | Способы и композиции для введения оксибутинина | |
| HRP20191151T1 (hr) | Oftalmološki farmaceutski sastav koji sadrži inhibitor ugljične anhidraze i metoda za pripremu istog |